Condition Directory

Prostate Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 27, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3910

Shown on this page

Current sort

How Prostate Cancer studies are organized in the registry

Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.

Terms that often appear in related listings

castration-resistant CRPC hormone-sensitive biochemical recurrence

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 205–216 of 3,910 matching trials for Prostate Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Survivorship, Prostate Cancer
Interventions: Acupuncture, Waitlist Control, Questionnaires; Procedure · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Neoplasms, Prostate
Interventions: GSK5458514; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Phoenix, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions: Questionnaires, Interviews, 30-minute telephone or videoconference sessions; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Coronary CT Angiography (CCTA); Device
Lead sponsor: Indiana University; Other
Eligibility: 40 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Coral Springs, Florida • Jeffersonville, Indiana • Holland, Michigan + 8 more

Conditions: Cancer Survivor, Prostate Carcinoma
Interventions: Educational Intervention, Laboratory Biomarker Analysis, Long-term Follow-up, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Male only
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant
Interventions: OP-3136, Fulvestrant, Palazestrant; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Gilbert, Arizona • Aurora, Colorado • Sarasota, Florida + 8 more

Conditions: Prostate Adenocarcinoma
Interventions: Survivorship Care Plan, Treatment Plan; Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 79
States / cities: Kingman, Arizona • Dublin, California • Oakland, California + 61 more

Conditions: Educational Materials for Genetic Testing, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions: Cognitive interview, LCAM intervention, Standard of care; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Brooklyn, New York • Jamaica, New York • New York, New York + 1 more

Conditions: Prostate Cancer
Interventions: AZD9750, AZD5305; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Duarte, California • Nashville, Tennessee

Conditions: Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
Interventions: Polygenic risk score (PRS); Diagnostic Test
Lead sponsor: Boston VA Research Institute, Inc.; Other
Eligibility: 50 Years to 70 Years
Enrollment: 1,071 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Androgen Therapy, Apalutamide, Docetaxel, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, PSMA PET Scan, Biospecimen Collection, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2039
U.S. locations: 213
States / cities: Tucson, Arizona • Dublin, California • Fremont, California + 172 more

About this Prostate Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Prostate Cancer clinical trials

How Prostate Cancer studies are organized in the registry

Filter and sort this condition

Live official records

An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

A Study of Mental Health Care in People With Cancer

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Long-Term Follow-Up in Patients With Prostate Cancer After Surgery

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

The Genomic Medicine at VA Study

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

About this Prostate Cancer clinical trials directory page